As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

After a surprisingly strong 2025, analysts believe an $800 price target for Tesla could be within reach in 2026.

With Instacart facing intense regulatory scrutiny, is this dip a buying opportunity or a warning sign to stay on the sidelines?

Despite a rocky year for Salesforce shares, Mizuho remains bullish on the stock, naming it a top software pick for 2026.

With trade and sports betting on the table now, investors contemplate HOOD stock.

After a strong second-quarter earnings showing, BlackBerry is now turning the spotlight to its upcoming third-quarter earnings this month.

Wall Street believes AppLovin has emerged as a standout GenAI contender for 2026, fueled by strong AI-led performance gains.

With Adobe now plugging into ChatGPT’s massive userbase, should investors buy, sell, or hold the stock at this point?

With Wall Street warning of an “EV Winter,” investors must decide if Tesla’s AI vision can keep the heat on.

Google’s comeback story is gaining speed, and investors wonder whether the stock can hit a fresh $400 target next year.